Genetic Test Gets Okayed By FDA: 4 Stocks To Keep An Eye On
Zacks Investment Research | Feb 26, 2020 08:42PM ET
In February, the FDA approved the marketing of the first test to detect a genetic disorder known as Fragile X Syndrome or FXS. The test is designed for use in adults who may be potential carriers of genetic alterations pertaining to FXS, also known as the FMR1 gene. This pathbreaking regulatory approval will enable genetic testing companies to expand their business in this niche as FXS is the leading monogenic cause of autism spectrum disorder, which is on the rise globally.
With rampant cutting-edge innovation by MedTech companies in the growing global genetic testing market and the readiness of regulatory bodies like FDA to support and validate such tests, there are a number of companies that deserve investors’ attention. Let us take a closer look.
Genetic Testing a Booming Space
Per a report by industry . The stock has lost 1% compared with the industry’s 2% fall. The company’s expected earnings growth rate for the next five years is 30%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.